Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Capital Expenditures: 2013-2024

Historic Capital Expenditures for Theravance Biopharma (TBPH) over the last 12 years, with Dec 2024 value amounting to $190,000.

  • Theravance Biopharma's Capital Expenditures fell 71.94% to $190,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $332,000, marking a year-over-year decrease of 86.66%. This contributed to the annual value of $332,000 for FY2024, which is 86.66% down from last year.
  • According to the latest figures from Q4 2024, Theravance Biopharma's Capital Expenditures is $190,000, which was up 1,166.67% from $15,000 recorded in Q3 2024.
  • In the past 5 years, Theravance Biopharma's Capital Expenditures registered a high of $2.4 million during Q2 2020, and its lowest value of -$57,000 during Q3 2022.
  • For the 3-year period, Theravance Biopharma's Capital Expenditures averaged around $282,667, with its median value being $151,500 (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 2,562.34% in 2020, then tumbled by 105.49% in 2022.
  • Over the past 5 years, Theravance Biopharma's Capital Expenditures (Quarterly) stood at $1.2 million in 2020, then slumped by 64.31% to $444,000 in 2021, then plummeted by 40.09% to $266,000 in 2022, then skyrocketed by 154.51% to $677,000 in 2023, then crashed by 71.94% to $190,000 in 2024.
  • Its Capital Expenditures stands at $190,000 for Q4 2024, versus $15,000 for Q3 2024 and $36,000 for Q2 2024.